Key Highlights
- NRx Pharmaceuticals reported that the FDA completed its initial ANDA evaluation of preservative-free ketamine.
- The FDA identified no significant drug-component flaws.
- The agency noted a vial-cap packaging concern, prompting a review restart.
- Management anticipates resolving the issue ahead of the projected 2026 commercial launch.
NRx Pharmaceuticals (NASDAQ: NRXP) reported that the FDA completed its initial ANDA evaluation of preservative-free ketamine, identifying no significant drug-component flaws.
What Happened
The agency noted a vial-cap packaging concern, prompting a review restart that management anticipates resolving ahead of the projected 2026 commercial launch.
Market Reaction
The disclosed information does not include stock price or trading data for NRx Pharmaceuticals following this regulatory update.
Outlook
Resolution of the vial-cap packaging concern and the restarted FDA review are likely to remain the key milestones determining whether the company's projected 2026 commercial launch timeline holds.
What did the FDA find in its initial ANDA evaluation?
No significant drug-component flaws, though the agency noted a vial-cap packaging concern.
What happens next in the review process?
The FDA has restarted its review, which management anticipates resolving ahead of the projected 2026 commercial launch.
What product is under review?
Preservative-free ketamine.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...